229 related articles for article (PubMed ID: 36453241)
21. Knockdown of Lncrna PVT1 Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Sponging Mir-195.
Wu D; Li Y; Zhang H; Hu X
Cell Physiol Biochem; 2017; 42(6):2453-2466. PubMed ID: 28848163
[TBL] [Abstract][Full Text] [Related]
22. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma.
Huang Y; Sheng H; Xiao Y; Hu W; Zhang Z; Chen Y; Zhu Z; Wu D; Cao C; Sun J
Radiother Oncol; 2021 Sep; 162():34-44. PubMed ID: 34214613
[TBL] [Abstract][Full Text] [Related]
23. Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Hamm CA; Pry K; Lu J; Bacus S
Exp Mol Pathol; 2019 Aug; 109():1-15. PubMed ID: 30953647
[TBL] [Abstract][Full Text] [Related]
24. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
25. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
26. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
27. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
28. Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1.
Liang F; Wang GZ; Wang Y; Yang YN; Wen ZS; Chen DN; Fang WF; Zhang B; Yang L; Zhang C; Han SC; Yang FY; Wang D; Liang LJ; Wang Z; Zhao Y; Wang CL; Zhang L; Zhou GB
Signal Transduct Target Ther; 2022 Sep; 7(1):311. PubMed ID: 36068203
[TBL] [Abstract][Full Text] [Related]
29. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
30. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy.
Ling C; Xie Y; Zhao D; Zhu Y; Xiang J; Yang J
Cancer Gene Ther; 2012 Oct; 19(10):697-706. PubMed ID: 22863759
[TBL] [Abstract][Full Text] [Related]
31. Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer.
Yuan M; Zhai Y; Men Y; Zhao M; Sun X; Ma Z; Bao Y; Yang X; Sun S; Liu Y; Zhang W; Hui Z
Oxid Med Cell Longev; 2022; 2022():5479491. PubMed ID: 35154567
[TBL] [Abstract][Full Text] [Related]
32. LncRNA SBF2-AS1 affects the radiosensitivity of non-small cell lung cancer via modulating microRNA-302a/MBNL3 axis.
Yu Z; Wang G; Zhang C; Liu Y; Chen W; Wang H; Liu H
Cell Cycle; 2020 Feb; 19(3):300-316. PubMed ID: 31928130
[No Abstract] [Full Text] [Related]
33. hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.
Wei D; Sun L; Feng W
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33880595
[TBL] [Abstract][Full Text] [Related]
34. Long noncoding HOXA11-AS knockdown suppresses the progression of non-small cell lung cancer by regulating miR-3619-5p/SALL4 axis.
Xia H; Niu Q; Ding Y; Zhang Z; Yuan J; Jin W
J Mol Histol; 2021 Aug; 52(4):729-740. PubMed ID: 34050851
[TBL] [Abstract][Full Text] [Related]
35. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
36. Circular RNA hsa_circ_0004396 acts as a sponge of miR-615-5p to promote non-small cell lung cancer progression and radioresistance through the upregulation of P21-Activated Kinase 1.
Li D; Yan L; Zhang J; Gu F
J Clin Lab Anal; 2022 Jun; 36(6):e24463. PubMed ID: 35500159
[TBL] [Abstract][Full Text] [Related]
37. CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells.
Zhang Y; Hu J; Ji K; Jiang S; Dong Y; Sun L; Wang J; Hu G; Chen D; Chen K; Tao Z
Cell Rep Med; 2023 Aug; 4(8):101151. PubMed ID: 37567173
[TBL] [Abstract][Full Text] [Related]
38. ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition.
Li Y; Sun C; Tan Y; Zhang H; Li Y; Zou H
Int J Biol Sci; 2021; 17(2):635-650. PubMed ID: 33613118
[No Abstract] [Full Text] [Related]
39. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
Front Immunol; 2022; 13():906815. PubMed ID: 36032151
[TBL] [Abstract][Full Text] [Related]
40. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
